Editorial: Assessment of osteoporotic fractures and risk prediction - Cheng X, Sheng ZF, Wang X.
Osteoporosis is a metabolic skeletal disorder that is characterized by low bone mineral density (BMD), a deterioration of the microstructure of bone tissue, and a decrease in bone strength, leading to an increase in bone fragility and the risk of fractures... (Source: SafetyLit)
Source: SafetyLit - January 9, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
DECT offers lower radiation dose alternative to perfusion CT
Dual-energy CT (DECT) performs comparably to perfusion CT for assessing angiogenesi...Read more on AuntMinnie.comRelated Reading:
5 ways dual-energy CT improves emergency room neuroimaging
Dual-energy CT shows promise for gout workup
Osteoporosis risk can be predicted on dual-energy CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 6, 2023 Category: Radiology Source Type: news
New Osteoporosis Guideline Says Start With a Bisphosphonate New Osteoporosis Guideline Says Start With a Bisphosphonate
Although the update to the 2017 ACP guideline on drug treatment for osteoporosis now advises bisphosphonates as initial therapy, an editorialist admits the decision to use them is not always easy.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 3, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
ACP Updates Living Guideline on Pharmacologic Treatment of Osteoporosis
TUESDAY, Jan. 3, 2023 -- In a living clinical guideline issued by the American College of Physicians (ACP) and published online Jan. 3 in the Annals of Internal Medicine, updated recommendations are presented for the pharmacologic treatment of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2023 Category: Pharmaceuticals Source Type: news
Bisphosphonates First for Osteoporosis; Youth T2D to Surge 700%; Insulin Cap Limits
(MedPage Today) -- Use bisphosphonates for the initial pharmacologic treatment of primary osteoporosis in men and postmenopausal women, the American College of Physicians recommended in its updated guidelines. (Annals of Internal Medicine)
Detection... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 3, 2023 Category: Endocrinology Source Type: news
Doctors' Group Updates Guidelines on Treating Osteoporosis
TUESDAY, Jan. 3, 2023 -- As millions of Americans born in the baby boomer generation are already finding out, bone loss is a common sign of aging.
And now experts at the American College of Physicians (ACP) — one of the leading groups representing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2023 Category: General Medicine Source Type: news
Mayo Clinic Q and A: Osteoporosis and supplements for bone health
DEAR MAYO CLINIC: My mother had osteoporosis and suffered a devastating fall in her early 60s that she never recovered from. I am 42, and I want to be proactive about my bone health. What screening do I need, and what if any supplements are necessary to optimize my bone health? What factors can help me maintain strong bones as I age? ANSWER: Osteoporosis is a condition that causes the bones to thin and lose their strength.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 28, 2022 Category: Databases & Libraries Source Type: news
Bidirectional Association for M énière Disease, Osteoporosis
THURSDAY, Dec. 22, 2022 -- Adults with Ménière disease (MD) have increased risk of osteoporosis, and those with osteoporosis have increased risk of MD, according to a study published online Nov. 18 in Nutrients.
Hyo Geun Choi, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Abaloparatide (Tymlos) for Osteoporosis in Men FDA Approves Abaloparatide (Tymlos) for Osteoporosis in Men
The FDA has approved abaloparatide (Tymlos) for increasing bone density in men with osteoporosis at high risk for fracture.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 22, 2022 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news
Radius Health scores FDA approval for its osteoporosis drug in men
Radius Health Inc. has managed to expand the use of its osteoporosis drug for the first time since 2017, when it was first approved by the U.S. Food and Drug Administration. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 21, 2022 Category: American Health Authors: Rowan Walrath Source Type: news
Radius Health ’s Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Cambridge, Mass., December 20, 2022– Radius Health, Inc. (“Radius” or the“Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos® (abaloparatide), a parathyroid hormone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2022 Category: Drugs & Pharmacology Source Type: news
A Lowell biotech will test its 'bone glue' in space
RevBio is behind a bone adhesive called Tetranite that holds together bones and allows them to regenerate. On Earth, the company is working on preparing it for use in osteoporosis patients. But in parallel, RevBio is testing it on the International Space Station. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 15, 2022 Category: American Health Authors: Rowan Walrath Source Type: news
GPs fail to identify osteoporosis sparking fears of a hidden epidemic of brittle bones
Family doctors are well placed to diagnose and treat osteoporosis - which causes brittle bones - but too many people are diagnosed only after a fall, the cross-party group of MPs and peers said. (Source: the Mail online | Health)
Source: the Mail online | Health - November 29, 2022 Category: Consumer Health News Source Type: news
Prolia (denosumab) by Amgen: Drug Safety Communication - FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis
FDA is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 23, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
High exposure to perfluoroalkyl substances in drinking water is associated with increased risk of osteoporotic fractures - a cohort study from Ronneby, Sweden - Xu Y, Hansson E, Andersson EM, Jakobsson K, Li H.
This study aimed to investigate the risks of osteoporotic fractures in a ... (Source: SafetyLit)
Source: SafetyLit - November 17, 2022 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news
